272BIO
LIVE

Serial Number

79314153

Owner

272BIO Limited

Attorney

Robert S. Broder

Filing Date

Apr 13, 2021

Add to watchlist:

No watchlists yet
View on USPTO

272BIO Trademark

Serial Number: 79314153 • Registration: 6886491

272BIO is a trademark filed by 272BIO Limited on April 13, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

272BIO Limited

Office C, Maple Barn, Beeches Farm Road

Entity Type: 24

Trademark Details

Filing Date

April 13, 2021

Registration Date

November 1, 2022

Published for Opposition

August 16, 2022

Goods & Services

Custom manufacture of veterinary preparations and medical preparations; custom manufacture of pharmaceutical preparations for veterinary and medical use; custom manufacture of biological preparations for veterinary and medical use; custom manufacture of biotechnological preparations for veterinary and medical use; custom manufacture of medicines including biotherapeutic medicines

Veterinary preparations for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; medical preparations for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; pharmaceutical preparations for veterinary and/or medical use for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; biological preparations for veterinary and medical use for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; biotechnological preparations for veterinary and medical use for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals; medicines, namely, antibody therapeutic preparations and veterinary vaccines for livestock; biotherapeutic medicines for the prevention and treatment of autoimmune diseases, central nervous system diseases, cancer, hematologic diseases, metabolic disorders, endocrine diseases, cardiovascular disease, immune system related diseases and disorders, infectious diseases, kidney diseases, liver diseases, gastrointestinal diseases, genetic conditions, inflammatory diseases, ophthalmological conditions, oncologic disorders, skin diseases and disorders, respiratory diseases, allergic diseases, neurological disorders, pain, and psychiatric disorder in livestock and other animals

Scientific research and development; biotechnological research and development; biotechnological research and development relating to animals and livestock; biotherapeutic product development; medical and veterinary laboratory services; clinical research in the field of veterinary preparations, biotherapeutic medicines, and antibodies; conducting clinical trials for others; information, advice and consultancy relating to the aforesaid services

Filing History

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 10, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 10, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 10, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 10, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 10, 2025 REAP
NEW REPRESENTATIVE AT IB RECEIVED
Feb 14, 2025 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Nov 8, 2024 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 14, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 22, 2023 FICS
FINAL DISPOSITION PROCESSED
Feb 22, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 1, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 1, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 1, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Aug 23, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 16, 2022 PUBO
CHANGE OF NAME/ADDRESS REC'D FROM IB
Aug 12, 2022 ADCH
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 27, 2022 OPNS
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 27, 2022 NONP
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 27, 2022 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 14, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 14, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 14, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 14, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 20, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 20, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 20, 2022 TROA
REFUSAL PROCESSED BY IB
Jan 23, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 6, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jan 6, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 9, 2021 RFCR
NON-FINAL ACTION WRITTEN
Dec 8, 2021 CNRT
ASSIGNED TO EXAMINER
Dec 4, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 2, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 28, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 25, 2021 REPR